(Q43926604)

28 November 2017

title

A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia (English)

1 reference

28 November 2017

0 references

0 references

1 reference

1 reference

1 reference

1 reference

5

1 reference

28 November 2017

Valentin Brodszky

1

1 reference

28 November 2017

Fanni Rencz

2

1 reference

28 November 2017

Márta Péntek

3

1 reference

28 November 2017

Petra Baji

4

1 reference

28 November 2017

László Gulácsi

6

1 reference

28 November 2017

publication date

10 July 2015

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

28 November 2017

published in

1 reference

28 November 2017

volume

16

1 reference

28 November 2017

issue

1

1 reference

28 November 2017

page(s)

119-125

1 reference

Epidemiology and natural history of inflammatory bowel diseases

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

The burden of inflammatory bowel disease in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Biological treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Statistical and regulatory considerations in assessments of interchangeability of biological drug products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Economical aspect of biological therapy in inflammatory conditions in Hungary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Adherence to biologic DMARD therapies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Budget-impact analyses: a critical review of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

A critical systematic review of budget impact analyses on drugs in the EU countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

The cost effectiveness and budget impact of natalizumab for formulary inclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2015.1067142

10.1586/14737167.2015.1067142

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference